Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;11(3):1835-1840.
doi: 10.3892/ol.2016.4133. Epub 2016 Jan 20.

Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2

Ruyi Hu  1 , Wenming Liu  2 , Xingfeng Qiu  3 , Zhenghe Lin  3 , Yan Xie  4 , Xingya Hong  5 , Reyila Paerhati  4 , Zhongquan Qi  4 , Guohong Zhuang  4 , Zhongchen Liu  6
Affiliations

Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2

Ruyi Hu et al. Oncol Lett. 2016 Mar.

Abstract

Tumor necrosis factor (TNF)-α-induced protein 8 (TIPE) is a recently identified protein that is considered to be associated with various malignancies, including esophageal, breast and pancreatic cancer; however, the importance of TIPE in gastric cancer (GC) remains unknown. Decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor superfamily that is expressed in digestive system neoplasms. The expression of DcR3 is regulated by the mitogen-activated protein kinase (MAPK)/MAPK kinase/extracellular signal-regulated kinase (ERK) signaling pathway. Reverse transcription-polymerase chain reaction was performed to detect the expression of TIPE, ERK and DcR3 in the pathological and tumor-adjacent normal gastric tissues of 30 patients that demonstrated stage III gastric adenocarcinoma. The expression and distribution of the TIPE protein was examined using immunohistochemistry, and the clinical significance and expression levels of DcR3 and ERK1/2 were evaluated. The expression of TIPE, ERK1/2 and DcR3 in the tumor tissues of GC was significantly increased compared with paracarcinoma tissues (P<0.05). In addition, TIPE expression positively correlated with DcR3 and ERK1 levels (r=0.538 and r=0.462, respectively; P<0.05). There was no statistical difference between tumor tissues from patients with varying age, gender, differentiation or lymph node metastasis (P>0.05). TIPE may be vital in the progression of GC. TIPE may be associated with the expression of DcR3 and ERK1/2, which may be involved in the cell apoptosis of GC. The present study elucidates the potential function of TIPE as a novel marker and therapeutic target for GC.

Keywords: GC; decoy receptor 3; extracellular signal-regulated protein kinases 1 and 2; tumor necrosis factor-α-induced protein 8.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Location of tumor necrosis factor-α-induced protein 8 in tissues analyzed using immunohistochemistry. (A) Stage III gastric cancer and (B) normal gastric mucosa (stain, 3,3′-diaminobenzidine tetrahydrochloride; magnification, ×10).
Figure 2.
Figure 2.
Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and normal tissues, analyzed using reverse transcription-polymerase chain reaction (normalized to β-actin).
Figure 3.
Figure 3.
Correlation between TIPE and DcR3 expression. TIPE, tumor necrosis factor-α-induced protein 8; DcR3, decoy receptor 3.
Figure 4.
Figure 4.
Correlation between TIPE and ERK1 expression. TIPE, tumor necrosis factor-α-induced protein 8; ERK1, extracellular signal-regulated protein kinase 1.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–477. doi: 10.1007/978-1-60327-492-0_23. - DOI - PubMed
    1. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477–490. doi: 10.1016/S0140-6736(09)60617-6. - DOI - PMC - PubMed
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. - DOI - PubMed
    1. Patel S, Wang FH, Whiteside TL, Kasid U. Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: Implications in metastasis and/or radiation response. Oral Oncol. 1997;33:197–203. doi: 10.1016/S0964-1955(96)00065-6. - DOI - PubMed
    1. Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I, Kasid U. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene. 2004;23:612–616. doi: 10.1038/sj.onc.1207123. - DOI - PubMed

LinkOut - more resources